Physician profile
David Valentine
NPI 1811094949
$1,053.56
in general payments reported to CMS, 2019-2025
11 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $135 · 2021: $104 · 2022: $209 · 2023: $185 · 2024: $28.33 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $433.86 | 2020-2023 | Wegovy |
| Gilead Sciences, INC. | $153.10 | 2019-2020 | |
| Glaxosmithkline, LLC. | $138.48 | 2025 | Nucala |
| Acadia Pharmaceuticals INC | $95.51 | 2024-2025 | Daybue |
| Abbvie INC. | $60.84 | 2023 | Botox |
| Ucb, INC. | $44.03 | 2022 | |
| Biodelivery Sciences International, INC. | $37.13 | 2019-2021 | |
| Janssen Biotech, INC. | $24.13 | 2025 | |
| Ge Healthcare | $24.13 | 2025 | |
| Lilly USA, LLC | $23.42 | 2022 | |
| Impel Pharmaceuticals INC. | $18.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Valentine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.